- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Brisbane Today
By the People, for the People
Sangamo Therapeutics Misses Q1 Earnings Estimates
Biopharmaceutical company reports $0.11 loss per share, well below analysts' $0.01 profit forecast
Mar. 30, 2026 at 10:18pm
Got story updates? Submit your updates here. ›
Sangamo Therapeutics' financial woes underscore the capital-intensive challenges facing biotech companies as they seek to advance their drug pipelines.Brisbane TodaySangamo Therapeutics (NASDAQ:SGMO), a clinical-stage biotech firm focused on gene therapy treatments, reported first-quarter financial results that fell short of Wall Street expectations. The company posted a loss of $0.11 per share, missing the consensus analyst estimate of $0.01 in earnings per share. Sangamo's revenue for the quarter was $14.23 million, well below the $40.25 million that analysts had projected.
Why it matters
Sangamo's weaker-than-expected financial performance raises concerns about the company's ability to fund its pipeline of experimental gene therapies, including its lead candidate ST-920 for Fabry disease. The miss also comes as Sangamo is transitioning to a clinical-stage neurology company, with several programs in early development.
The details
Sangamo attributed the revenue shortfall to delays in its Fabry disease program, noting that the Biologics License Application (BLA) submission and broader operations are contingent on securing additional funding and a commercialization partner. The company said it has limited cash resources despite raising over $130 million in 2025 and managing expenses to extend its runway.
- Sangamo reported its Q1 2026 financial results on March 30, 2026.
The players
Sangamo Therapeutics
A clinical-stage biopharmaceutical company that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology.
What’s next
Sangamo will need to secure additional funding and a commercialization partner for its Fabry disease program in order to complete the BLA submission and advance its broader pipeline.
The takeaway
Sangamo's disappointing Q1 results highlight the challenges facing the company as it transitions to a clinical-stage neurology focus while also needing to find a partner and additional financing for its lead Fabry disease program. Investors will be closely watching Sangamo's ability to execute on its strategic priorities in the coming quarters.
